A phase II trial to assess daclatasvir, in combination with asunaprevir, and asunaprevir/beclabuvir/daclatasvir in patients co-infected with genotype 1 hepatitis C, and HIV, who are naive to directly-acting antivirals and are receiving antiretrovirals

Trial Profile

A phase II trial to assess daclatasvir, in combination with asunaprevir, and asunaprevir/beclabuvir/daclatasvir in patients co-infected with genotype 1 hepatitis C, and HIV, who are naive to directly-acting antivirals and are receiving antiretrovirals

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Asunaprevir (Primary) ; Asunaprevir/becabluvir/daclatasvir (Primary) ; Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms CONQUER
  • Most Recent Events

    • 20 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top